Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

Obstetrics and Gynecology

Volumn 107, Issue 1, 2006, Pages 77-85

  Aletti, Giovanni D ^a   Dowdy, Sean C ^a   Gostout, Bobbie S ^a   Jones, Monica B ^a   Stanhope, C Robert ^a   Wilson, Timothy O ^a   Podratz, Karl C ^a   Cliby, William A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOSIS; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; AGE; ANALYSIS OF VARIANCE; CANCER INVASION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; RISK ASSESSMENT; SURVIVAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; OVARIECTOMY; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 32644455276     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000192407.04428.bb     Document Type: Article

References (21)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005 [published erratum appears in CA Cancer J Clin 2005;55:259]. CA Cancer J Clin 2005;55:10-30.
2. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
3. Randall TC, Rubin SC. Cytoreductive surgery for ovarian cancer. Surg Clin North Am 2001;81:871-83.
4. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55 suppl:S91-6.
5. Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol 2001;83:286-91.
6. Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003;197:565-74.
7. Chen LM, Leuchter RS, Lagasse LD, Karlan BY. Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 2000;77:362-8.
8. Montz FJ, Schlaerth JB, Berek JS. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol 1989;35:338-40.
9. Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 2003;89:16-21.
10. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 2001;82:435-41.
11. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma. Part V: the impact of physician's specialty on patients' survival. Cancer 1993;72:3663-70.
12. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001;82:489-97.
13. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991;40:195-200.
14. Farias-Eisner R, Teng F, Oliveira M, Leuchter R, Karlan B, Lagasse LD, et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994;55:108-10.
15. Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, et al. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998;82:159-67.
16. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67:208-14.
17. Announcements: FIGO stages-1988 revision. Gynecol Oncol 1989;35:125-7.
18. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002;8 suppl 1:S22-30.
19. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
20. Berman ML. Future directions in the surgical management of ovarian cancer. Gynecol Oncol 2003;90 suppl:S33-9.
21. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004;94:650-4.